TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03264547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Every week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Administered for 2 weeks and is then stopped to be administered for 1 week
Study: NCT02146092

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Standard of care exercise training and supervision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Standard of care exercise training and supervision
Study: NCT04131010

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single operator video cholangioscopy
Description: The technique provides digital imaging with a higher resolution and improved maneuverability compared to the legacy fiberoptic system. In addition, the working channel was enlarged to a diameter of 1.3 mm. Retrospective data showed an overall technical success rate for single-operator video pancreatoscopy (SOVP) guided treatment of pancreatic stones of 95%
Study: NCT04295018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+T cells/kg. Other Name: CBM.BCMA Chimeric Antigen Receptor T cell.
Study: NCT00757978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: memantine
Description: memantine 10mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 capsule of placebo twice a day
Study: NCT02969629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT00255944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Youthnet Internet-based program
Description: Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Internet based program
Description: The control program will deliver standard STD/HIV prevention messages.
Study: NCT04052932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose1
Description: tablets，dose1，QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR4640 dose2
Description: tablets，dose2，QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: tablets，QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 MG
Description: tablets，300mg，QD
Study: NCT01129115

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nonexercise control group
Description: Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group 1
Description: The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
Study: NCT04226495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Infusion
Description: Intra-operative sufentanil infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil Bolus
Description: Intra-operative sufentanil bolus
Study: NCT01129115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group 2
Description: The 100% group will perform 150 minutes a week of exercise over 3 - 5 days

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Group 3
Description: The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
Study: NCT01797978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous methylene blue administration
Description: Initial history taking and physical examination --\> enrollment --\> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02189577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 5259
Description: Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
Study: NCT01530477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lunar Prodigy (GEHC)
Description: Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lunar Prodigy (GEHC)
Description: Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lunar Prodigy (GEHC)
Description: Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
Study: NCT02879708

Intervention type: OTHER
Group type: OTHER
Intervention: Information Only
Description: Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.

Intervention type: OTHER
Group type: OTHER
Intervention: Information and Facilitation
Description: In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
Study: NCT03953105

Intervention type: DEVICE
Intervention: ePER
Description: usind the ePER for weight estimation and suggestion of the defined parameter

Intervention type: DEVICE
Intervention: ePER
Description: usind the ePER for weight estimation and suggestion of the defined parameter

Intervention type: DEVICE
Intervention: BT
Description: usind the BT for weight estimation and suggestion of the defined parameter

Intervention type: DEVICE
Intervention: BT
Description: usind the BT for weight estimation and suggestion of the defined parameter
Study: NCT03226678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor
Study: NCT02927041

Intervention type: DEVICE
Intervention: transesophageal echocardiography (hTEE)
Description: Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.

Intervention type: DEVICE
Intervention: transesophageal echocardiography (hTEE)
Description: Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
Study: NCT04241393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon tablet
Description: Participants will receive multiple dose titration of Tavapadon (0.25 mg once daily \[QD\] on Days 1 to 3, 0.5 mg QD on Days 4 to 6, 1.0 mg QD on Days 7 to 9, 1.5 mg QD on Days 10 to 12, and 2.5 mg QD on Days 13 to 15)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon [14C] suspension
Description: Following 15-Day multiple dose titration of Tavapadon, participants will receive a single oral dose of Tavapadon 2.5 mg containing approximately 100 μCi of \[14C\] Tavapadon on Day 16
Study: NCT03611582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous (s.c., under the skin) injections of semaglutide once weekly at escalating doses (0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: S.c. injections of placebo once weekly at a similar dose escalation manner as semaglutide (placebo matched to semaglutide 0.25 mg/week, 0.5 mg/week, 1.0 mg/week, 1.7 mg/week, 2.4 mg/week). The dose will be escalated to next level every 4 weeks.
Study: NCT04686266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Information + Health Coaching
Description: Virtual Health Coaching for You: The focus of these sessions is helping caregivers take care of themselves. These are virtual health coaching sessions by trained Health Coaches over 6 months with content based on the theoretical framework from our prior research
Study: NCT04507893

Intervention type: OTHER
Intervention: Clinical, laboratory and imaging characteristics of pneumonia
Description: Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients.

Intervention type: OTHER
Intervention: Clinical, laboratory and imaging characteristics of pneumonia
Description: Evaluation of the clinical, laboratory and imaging characteristics in patients with clinical presentation suggestive of COVID-19 infection, classified according to the results of PCR assay for COVID-19 on naso-pharyngeal swab as COVID-19 patients and negative COVID-19 patients.
Study: NCT02077413

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Muscle Group
Description: Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretch-Contract Pre-rehabilitation Group
Description: All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of \~5 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stretch-Contract Control Group
Description: All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Atrophy
Description: These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
Study: NCT03725774

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GRIP (Getting Research into Practice) model
Description: The intervention will consist of the use of the GRIP (Getting Research into Practice) model and implementation of its strategies in clinical practice, according to the study unit in question and the scope of action.~The GRIP model is a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying the obstacles to improvements in clinical practice, and drawing up and implementing a plan of action for the purpose of improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the obstacles that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
Study: NCT03099694

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: noninvasive high-frequency ventilation (nHFOV)
Description: NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure (nCPAP)
Description: Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA)
Study: NCT04394793

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose radiation therapy
Description: Patient will be treated with a dose of 70 cGy in one fraction radiation therapy in addition to standard therapy
Study: NCT01068626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for rosuvastatin
Description: once daily
Study: NCT00662558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: 200 mg capsules BID for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol HCL
Description: 50 mg capsules QID for 6 weeks
Study: NCT01894659

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% oral sucrose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30% oral glucose
Study: NCT03017027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy dog visitation (TDV)
Description: The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: non-TDV control
Description: Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
Study: NCT04683354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085
Description: HL-085 is a MEK inhibitor with potential indication for cancers. It will be given twice or three times daily continuously in the study until disease progression; or the risks outweigh the benefits, if the subject continues study treatment; or subjects with poor compliance; or subjects need to receive or have already started alternative antitumor drugs; or Subjects who need to receive or have already started alternative any other concomitant medication and/or treatment, which would significantly impact their safety; or interruption of IP administration for more than 14 days due to IP-related AEs.
Study: NCT03858894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution QD
Description: DE-117 ophthalmic solution QD and Vehicle (no active DE-117 ingredient) QD add one drop in each eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution BID
Description: DE-117 ophthalmic solution BID twice Daily (20:00 and 8:00) add one drop in each eye
Study: NCT00583102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin
Description: Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
Study: NCT03069456

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADMS
Study: NCT01393132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymosin Beta 4 eye drops
Description: Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Control
Description: Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
Study: NCT00627809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Streptokinase
Description: intracoronary infusion, 250.000 Units

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: primary percutaneous coronary intervention
Description: balloon catheter, stent

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary percutaneous coronary intervention
Description: balloon catheter, stent
Study: NCT05032456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculus Quest All-in-one VR Gaming Headset (128 GB) VR system
Description: The laboring women who enrolled in the VR group were offered to choose among several virtual environments including orange sunset, green meadows, black beginning, red savannah, blue deep, blue moon, blue ocean, white winter, and red fall. Cards printed out from the screenshots of the Nature Trek application representing these novel immersion options were provided to the patients to help them pick up their preferred environment in advance.
Study: NCT02014922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraTears® Lubricant Eye Drop

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TheraTears® preservative-free single-use containers

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TheraTears® Nutrition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTears® TheraLid® Eyelid Cleanser
Study: NCT03202069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Even protein
Description: Intake of even protein 5 day rotating menu

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skewed protein
Description: Intake of skewed protein 5 day rotating menu
Study: NCT01214252

Intervention type: DEVICE
Intervention: Permacol Surgical Implant
Description: Permacol Surgical Implant
Study: NCT01530477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lunar iDXA (GEHC)
Description: Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lunar iDXA (GEHC)
Description: Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lunar iDXA (GEHC)
Description: Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discovery A (Hologic
Description: Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discovery A (Hologic
Description: Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Discovery A (Hologic
Description: Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements